The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Hernández Pérez JM, Acosta Fernández O, Castro López-Tarruella V

[Gold salt-induced lung disease].

Archivos de bronconeumologia. 2004;40(11):540

Sinha A, Silverstone EJ, O'Sullivan MM

Gold-induced pneumonitis: computed tomography findings in a patient with rheumatoid arthritis.

Rheumatology (Oxford, England). 2001;40(6):712-4

Reinicke C

[Pulmonary side effects of gold treatment].

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete. 1981;36(24):969-72

Levinson ML, Lynch JP 3rd, Bower JS

Reversal of progressive, life-threatening gold hypersensitivity pneumonitis by corticosteroids.

The American journal of medicine. 1981;71(5):908-12

Heyd J, Simmeran A

Gold-induced lung disease.

Postgraduate medical journal. 1983;59(692):368-70

Bellelli A, Boiardi L, Tumiati B, Brigati C

Diffuse interstitial lung disease associated with hypersensitivity to gold salt.

Clinical and experimental rheumatology. 1985;3(2):181-2

Agarwal R, Sharma SK, Malaviya AN

Gold-induced hypersensitivity pneumonitis in a patient with rheumatoid arthritis.

Clinical and experimental rheumatology. 1989;7(1):89-90

Fernández Casares M, Casas HA, Leczycki H

[Pulmonary toxicity of gold salts].

Medicina. 1991;51(1):59-61